Ready to FLIP THE SCRIPT? How to Prescribe IBSRELA

Treatment for IBS-C Is Not One Size Fits All. When Your Patients Aren’t Getting Adequate Relief, Try a Therapy With a Different Mechanism of Action in a Different Class^1-3

IBSRELA is dosed as one (1) 50-mg tablet BID

Instruct Patients as Follows²:

Take IBSRELA immediately prior to breakfast or the first meal of the day and immediately prior to dinner

If a dose is missed, skip the missed dose and take the next dose at the regular time

Do not take 2 doses at the same time

How to Prescribe Through the IBSRELA Pharmacy Network

Identify IBS-C patients who may benefit from IBSRELA

Adult patients with a diagnosis of IBS-C (ICD-10: K58.1)²*

e-Prescribe IBSRELA 50 mg BID through the IBSRELA Pharmacy Network. IBSRELA may be available at other pharmacies

Most insurances require a PA; CoverMyMeds^® is available to quickly and accurately submit the PA when a prescription is initiated

Patients can pay as little as $0^†—discount applied automatically at pharmacy

*The ICD-10 code is provided for informational purposes only. It is the treating physician’s responsibility to determine the proper diagnosis, treatment, and applicable ICD-10 code. Ardelyx, Inc. does not guarantee coverage or reimbursement for the product.
All trademarks, logos, and brand names are the property of their respective owners.

PA=prior authorization.

Coming Soon: The IBSRELA Pharmacy Network will be available Monday, November 3.

Ardelyx Offers Several Programs to Support Patient Affordability

Commercial patients can pay as little as zero dollars

Commercially insured patients can pay as little as $0^† per 30- or 90-day prescription through the IBSRELA Copay Program
ArdelyxAssist offers additional programs for eligible patients who are uninsured or underinsured and are unable to afford IBSRELA

ArdelyxAssist is here to help. Call us at 844‑427‑7352, option 1, if you have any questions or need support with IBSRELA access or affordability

^†Program Disclosure: The Copay Assistance Program is available to patients only for “on-label” use. To be eligible for the IBSRELA Commercial Copay Program, patients must meet the following criteria:

Have active commercial insurance and IBSRELA is covered on the insurance
Must not have a prescription adjudicated with full or partial coverage from Medicare (B, C, or D), Medicaid, Medigap, CHAMPUS, VA, DOD, Tricare, State Pharmaceutical Assistance Programs, or any other Government Funded Plans
- Important Note: Mail Handlers Beneﬁt Program (MHBP), the Blue Cross Blue Shield Federal Employee Program (FEP), or qualiﬁed health plans purchased under a federal or state exchange under the Affordable Care Act are excluded from the above requirement
Reside in the United States or a United States territory (as permitted by state law)

Additional terms and conditions of the program.

Resources for You and Your Patients

IBSRELA Copay Program Download copay card

Sample Letter of Medical Necessity Download template

ARE YOUR PATIENTS READY TO FLIP THE SCRIPT? ASK THEM, “DO YOU WANT TO TRY SOMETHING DIFFERENT?”

Peer Perspectives

“The majority of my patients report they are happy with IBSRELA and want to continue on the medication.”

—Dr Jignesh Shah

Compensated advisor to Ardelyx

References:

1. Saha L. Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine. World J Gastroenterol. 2014;20(22):6759-6773. 2. IBSRELA [prescribing information]. Waltham, MA: Ardelyx, Inc.; 2025. 3. Brenner DM. Mechanism of action considerations in the management of IBS-C. Gastroenterol Hepatol (N Y). 2023;19(12):749-756.

INDICATION

IBSRELA (tenapanor) is indicated for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in adults.

IMPORTANT SAFETY INFORMATION

WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS

IBSRELA is contraindicated in patients less than 6 years of age; in nonclinical studies in young juvenile rats administration of tenapanor caused deaths presumed to be due to dehydration. Avoid use of IBSRELA in patients 6 years to less than 12 years of age. The safety and effectiveness of IBSRELA have not been established in patients less than 18 years of age.

CONTRAINDICATIONS

IBSRELA is contraindicated in patients less than 6 years of age due to the risk of serious dehydration.
IBSRELA is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.

WARNINGS AND PRECAUTIONS

Risk of Serious Dehydration in Pediatric Patients

IBSRELA is contraindicated in patients below 6 years of age. The safety and effectiveness of IBSRELA in patients less than 18 years of age have not been established. In young juvenile rats (less than 1 week old; approximate human age equivalent of less than 2 years of age), decreased body weight and deaths occurred, presumed to be due to dehydration, following oral administration of tenapanor. There are no data available in older juvenile rats (human age equivalent 2 years to less than 12 years).
Avoid the use of IBSRELA in patients 6 years to less than 12 years of age. Although there are no data in older juvenile rats, given the deaths in younger rats and the lack of clinical safety and efficacy data in pediatric patients, avoid the use of IBSRELA in patients 6 years to less than 12 years of age.

Diarrhea

Diarrhea was the most common adverse reaction in two randomized, double-blind, placebo-controlled trials of IBS-C. Severe diarrhea was reported in 2.5% of IBSRELA-treated patients. If severe diarrhea occurs, suspend dosing and rehydrate patient.

MOST COMMON ADVERSE REACTIONS

The most common adverse reactions in IBSRELA-treated patients (incidence ≥2% and greater than placebo) were: diarrhea (16% vs 4% placebo), abdominal distension (3% vs <1%), flatulence (3% vs 1%) and dizziness (2% vs <1%).